AMAG snags Cord Blood Registry for $700M

AMAG Pharmaceuticals has stepped in to buy Cord Blood Registry for $700 million, capturing about half of the privately stored cord blood units and taking a prominent position as supplier of stem cells to R&D groups. As Bloomberg notes, this deal further beefs up Waltham, MA-based AMAG's position in the maternal health field, following last November's acquisition of the maternal health unit of Lumara Health. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.